查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1709466

肺纖維化生物標記市場，依生物標記類型、應用、最終用戶、國家和地區分類－2025 年至 2032 年全球產業分析、市場規模、市場佔有率及預測

Pulmonary Fibrosis Biomarkers Market, By Type of Biomarkers, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年肺纖維化生物標記市場規模價值 42.9043 億美元，2025 年至 2032 年的複合年成長率為 4.50%。

肺纖維化生物標記市場-市場動態

肺纖維化發生率的上升推動了對診斷生物標記的需求。

肺纖維化（PF）發生率的不斷上升是生物標記市場成長的主要驅動力。在印度等國家，特發性肺纖維化 (IPF) 的盛行率正在上升，估計每 10 萬人中有 14 至 43 人患有此病。病例數的不斷成長凸顯了早期準確診斷的迫切需求。一項研究顯示，特發性肺纖維化 (IPF) 約佔全國所有間質性肺病 (ILD) 的 17%，這強調了及早發現病情以有效控制的重要性。此外，浦那等地區的特發性肺纖維化病例每年增加 5-7%，這進一步凸顯了對先進診斷工具的需求。隨著全球肺纖維化病例持續上升，對能夠診斷、監測病情進展和評估治療效果的可靠生物標記的需求比以往任何時候都更加重要，從而推動了該市場對創新的需求。

肺纖維化生物標記市場—關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 4.50%。

根據生物標記類型的細分，預計診斷生物標記將在 2024 年佔據最大市場佔有率

根據應用細分，診斷是 2024 年的主要應用

根據最終用戶細分，診斷實驗室是 2024 年領先的最終用戶

按地區分類，北美是 2024 年最大的收入來源

肺纖維化生物標記市場-細分分析：

全球肺纖維化生物標記市場根據生物標記的類型、應用、最終用戶和地區進行細分。

根據生物標記的類型，市場分為三類：診斷生物標記、預後生物標記、預測生物標記。診斷生物標記部分是肺纖維化生物標記市場中最突出和最重要的部分。早期準確診斷肺纖維化 (PF) 對於改善患者預後至關重要，而診斷生物標記在此過程中發揮著至關重要的作用。這些生物標記對於在早期階段識別 PF 的存在至關重要，此時干預仍可減緩疾病進展。由於特發性肺纖維化 (IPF) 等疾病與其他肺部疾病相似，因此診斷起來具有挑戰性，診斷生物標記有助於區分 PF 與其他疾病，從而實現更快、更準確的診斷。 KL-6、SP-D 和 CCL18 等生物標記在臨床環境中擴大用於輔助診斷 IPF 和其他形式的肺纖維化。人們對 PF 的認知不斷提高以及其在美國等地區的高發病率進一步加劇了對可靠診斷工具的需求。這種需求推動了新的、更有效的生物標記的研究和開發，確保診斷生物標記領域在市場上保持主導地位。

根據應用，市場分為三類：診斷、治療監測、藥物開發。診斷部分是肺纖維化生物標記市場中最重要的部分。早期準確診斷肺纖維化 (PF) 對於改善患者預後和及時治療至關重要。由於 PF，特別是特發性肺纖維化 (IPF)，與其他肺部疾病具有相同的症狀，因此經常被誤診，因此診斷生物標記對於將其與類似疾病區分開來至關重要。 KL-6、SP-D 和 CCL18 等生物標記通常用於臨床實踐，因為它們能夠在早期階段檢測 PF，而此時干預措施對於減緩疾病進展最為有效。隨著 PF 盛行率的上升，對精確診斷工具的需求也日益增加，從而推動了人們對開發用於早期檢測的新生物標記的關注。此外，由於研究機構和醫療保健提供者強調早期診斷，診斷應用仍然是肺纖維化生物標記市場成長和創新的核心。

肺纖維化生物標記市場—地理洞察

北美是肺纖維化生物標記市場的領先地區，因為它擁有先進的醫療保健基礎設施、高發病率的肺部疾病以及正在進行的研究計劃。尤其是美國，憑藉其頂級研究機構、製藥公司以及越來越多的臨床試驗，佔據了相當大的市場。美國約有 20 萬人被診斷出患有特發性肺纖維化 (IPF)，因此迫切需要診斷生物標記來幫助早期發現和管理。此外，美國國立衛生研究院 (NIH) 等政府計畫正在資助識別和驗證生物標記的研究，以促進創新。該地區強大的醫療保健報銷系統也確保新興的生物標記被應用於臨床實踐。此外，人們對疾病的認知不斷提高以及個人化醫療的進步進一步推動了市場的成長。

美國憑藉其先進的醫療保健體系和對醫學研究的大量投資，在肺纖維化生物標記市場中佔據主導地位。目前有超過 20 萬人被診斷出患有特發性肺纖維化 (IPF)，對早期檢測、預後和治療監測的有效生物標記的需求正在迅速成長。

美國政府透過國立衛生研究院（NIH）等機構大力資助新生物標記的研究。這反過來又加速了 IPF 診斷工具和治療方法的發展。該國還擁有強大的製藥業，積極與研究機構合作，推動生物標記驅動的解決方案

肺纖維化生物標記市場-競爭格局：

肺纖維化生物標記市場的競爭格局以老牌製藥巨頭和專業生物技術公司的存在為標誌。基因泰克、羅氏和吉利德科學等主要公司憑藉其在肺部疾病領域的廣泛研究能力和強大的產品組合佔據了市場主導地位。

這些公司專注於推進生物標記的發現、進行臨床試驗以及將生物標記整合到治療方案中。同時，Biodesix 和賽默飛世爾科技等規模較小的生物科技公司正在利用針對肺纖維化的創新生物標記平台和診斷工具取得重大進展。競爭環境也受到製藥公司和研究機構之間策略合作的推動，旨在加速生物標記的驗證和商業化。隨著市場的發展，越來越多的公司採用個人化醫療方法，進一步加劇了競爭。

最新動態：

2023年10月，百時美施貴寶宣布，美國食品藥物管理局（FDA）授予首創口服溶血磷脂酸受體1（LPA1）拮抗劑BMS-986278突破性療法認定，用於治療一種嚴重且危及生命的疾病－進行性肺纖維化（PPF）。這項頭銜擴大了該公司的產品組合。

2020 年 3 月，百時美施貴寶與肺纖維化基金會 (PFF) 達成合作，以識別生物標記。此次合作旨在加速針對此難題的標靶療法的開發，體現了該公司致力於改善患者治療效果的承諾。這項措施有助於提高銷售額和收入。

目錄

第1章：肺纖維化生物標記市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 肺纖維化生物標記市場片段（依生物標記類型）
    • 肺纖維化生物標記市場片段（依應用）
    • 肺纖維化生物標記市場片段（按最終用戶）
    • 肺纖維化生物標記市場（按國家/地區）
    • 肺纖維化生物標記市場（按地區）
  • 競爭洞察

第3章：肺纖維化生物標記主要市場趨勢

  • 肺纖維化生物標記市場促進因素
    • 市場促進因素的影響分析
  • 肺纖維化生物標記市場限制
    • 市場限制的影響分析
  • 肺纖維化生物標記市場機遇
  • 肺纖維化生物標記市場未來趨勢

第4章：肺纖維化生物標記產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：肺纖維化生物標記市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：肺纖維化生物標記市場格局

  • 2024年肺纖維化生物標記市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：肺纖維化生物標記市場－依生物標記類型

  • 概述
    • 按生物標記類型分類的細分市場佔有率分析
    • 診斷生物標記
    • 預後生物標記
    • 預測性生物標記

第 8 章：肺纖維化生物標記市場 - 按應用

  • 概述
    • 按應用細分市場佔有率分析
    • 診斷
    • 治療監測
    • 藥物開發

第9章：肺纖維化生物標記市場－按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院和診所
    • 診斷實驗室
    • 研究與學術機構

第 10 章：肺纖維化生物標記市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美肺纖維化生物標記主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（依生物標記類型）
    • 北美市場規模和預測（按應用）
    • 北美市場規模及預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲肺纖維化生物標記主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依生物標記類型）
    • 歐洲市場規模和預測，按應用
    • 歐洲市場規模及預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區肺纖維化生物標記主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區生物標記市場規模及預測
    • 亞太地區市場規模及預測（按應用）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲肺纖維化生物標記主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依生物標記類型）
    • 拉丁美洲市場規模及預測（按應用）
    • 拉丁美洲市場規模及預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲肺纖維化生物標記主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依生物標記類型）
    • MEA 市場規模及預測（按應用）
    • MEA 市場規模及預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 11 章：關鍵供應商分析-肺纖維化生物標記產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Biodesix, Inc.
    • Genentech, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • PerkinElmer, Inc.
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • Novartis International AG
    • Johnson & Johnson
    • Mylan NV
    • Sanofi SA
    • Amgen Inc.

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4936

REPORT HIGHLIGHT

Pulmonary Fibrosis Biomarkers Market size was valued at US$ 4,290.43 Million in 2024, expanding at a CAGR of 4.50% from 2025 to 2032.

Pulmonary fibrosis biomarkers are biological indicators that help in the diagnosis, monitoring, and prognosis of pulmonary fibrosis, a progressive lung disease characterized by scarring of lung tissue. These biomarkers can be proteins, genes, or other molecules present in blood, urine, or tissue samples. They assist in understanding the disease's progression and response to treatment. Biomarkers such as KL-6, SP-D, and CCL18 are often used to monitor disease activity and predict outcomes. Research into pulmonary fibrosis biomarkers is crucial for early detection, personalized treatments, and the development of new therapies. These biomarkers also help differentiate pulmonary fibrosis from other lung diseases with similar symptoms. As the disease can be difficult to diagnose, biomarkers provide valuable insights for clinicians to make more accurate decisions. With ongoing studies, these biomarkers are increasingly seen as essential tools for better patient management.

Pulmonary Fibrosis Biomarkers Market- Market Dynamics

Rising incidence of pulmonary fibrosis drives demand for biomarkers in diagnosis.

The increasing incidence of pulmonary fibrosis (PF) is a key driver for the growth of the biomarkers market. In countries like India, the prevalence of idiopathic pulmonary fibrosis (IPF) is rising, with estimates ranging between 14 to 43 per 100,000 people. This growing number of cases highlights the urgent need for early and accurate diagnosis. A study revealed that IPF accounts for approximately 17% of all interstitial lung diseases (ILDs) in the country, emphasizing the importance of detecting the condition early to manage it effectively. Furthermore, regions like Pune have seen a 5-7% annual increase in IPF cases, which further underscores the demand for advanced diagnostic tools. As pulmonary fibrosis cases continue to rise globally, the need for reliable biomarkers that can diagnose, monitor disease progression, and assess treatment efficacy is more critical than ever, driving the demand for innovation in this market.

Pulmonary Fibrosis Biomarkers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.50% over the forecast period (2025-2032)

Based on Type of Biomarkers segmentation, Diagnostic Biomarkers was predicted to show maximum market share in the year 2024

Based on application segmentation, Diagnosis was the leading application in 2024

Based on End-user segmentation, Diagnosis laboratories was the leading End-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pulmonary Fibrosis Biomarkers Market- Segmentation Analysis:

The Global Pulmonary Fibrosis Biomarkers Market is segmented on the basis of Type of Biomarkers, Application, End-user, and Region.

The market is divided into three categories based on Type of Biomarkers: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers. The Diagnostic Biomarkers segment is the most prominent and significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes, and diagnostic biomarkers play a vital role in this process. These biomarkers are essential in identifying the presence of PF at its early stages, when intervention can still slow disease progression. With diseases like idiopathic pulmonary fibrosis (IPF) being challenging to diagnose due to their similarities with other lung conditions, diagnostic biomarkers help differentiate PF from other diseases, leading to quicker and more accurate diagnoses. Biomarkers such as KL-6, SP-D, and CCL18 are increasingly being used in clinical settings to aid in diagnosing IPF and other forms of pulmonary fibrosis. The growing awareness of PF and its high incidence rate in regions like the U.S. further intensifies the need for reliable diagnostic tools. This demand is driving the research and development of new, more efficient biomarkers, ensuring that the diagnostic biomarkers segment remains dominant in the market.

The market is divided into three categories based on application: Diagnosis, Treatment Monitoring, Drug Development. The diagnosis segment is the most significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes and enabling timely treatments. Since PF, particularly idiopathic pulmonary fibrosis (IPF), shares symptoms with other lung diseases, it is often misdiagnosed, making diagnostic biomarkers vital for distinguishing it from similar conditions. Biomarkers such as KL-6, SP-D, and CCL18 are commonly used in clinical practice for their ability to detect PF at early stages, when interventions are most effective in slowing disease progression. With the rising prevalence of PF, there is an increasing demand for precise diagnostic tools, driving the focus on developing new biomarkers for early detection. Moreover, as research institutions and healthcare providers emphasize early diagnosis, the diagnostic application remains central to the growth and innovation in the pulmonary fibrosis biomarkers market.

Pulmonary Fibrosis Biomarkers Market- Geographical Insights

North America is a leading region in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare infrastructure, high prevalence of pulmonary diseases, and ongoing research initiatives. The United States, in particular, has a significant share in the market, supported by the presence of top-tier research institutions, pharmaceutical companies, and a growing number of clinical trials. With approximately 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF) in the U.S., there is a strong demand for diagnostic biomarkers to aid early detection and management. Furthermore, government programs, like the National Institutes of Health (NIH), are funding research to identify and validate biomarkers, boosting innovation. The region's strong healthcare reimbursement systems also ensure that emerging biomarkers are adopted into clinical practice. Additionally, rising awareness about the disease and advancements in personalized medicine are further propelling market growth.

The United States plays a dominant role in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare system and substantial investment in medical research. With over 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF), the demand for effective biomarkers for early detection, prognosis, and treatment monitoring is growing rapidly.

The U.S. government, through agencies like the National Institutes of Health (NIH), is heavily funding research to discover new biomarkers. This, in turn, accelerates the development of diagnostic tools and therapies for IPF. The country also boasts a robust pharmaceutical industry that actively collaborates with research institutions to advance biomarker-driven solutions

Pulmonary Fibrosis Biomarkers Market- Competitive Landscape:

The competitive landscape of the Pulmonary Fibrosis Biomarkers market is marked by the presence of both established pharmaceutical giants and specialized biotech companies. Major players like Genentech, F. Hoffmann-La Roche, and Gilead Sciences dominate the market due to their extensive research capabilities and robust portfolios in pulmonary diseases.

These companies focus on advancing biomarker discovery, conducting clinical trials, and integrating biomarkers into treatment protocols. At the same time, smaller biotech firms like Biodesix and Thermo Fisher Scientific are making significant strides with innovative biomarker platforms and diagnostic tools tailored for pulmonary fibrosis. The competitive environment is also driven by strategic collaborations between pharmaceutical companies and research institutions, aimed at accelerating biomarker validation and commercialization. As the market evolves, companies are increasingly adopting personalized medicine approaches, further intensifying competition.

Recent Developments:

In October 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for BMS-986278, a first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a severe and life-threatening disease. This designation expanded the company's product portfolio.

In March 2020, Bristol Myers Squibb entered into a collaboration with the Pulmonary Fibrosis Foundation (PFF) to identify biomarkers. The partnership aimed to accelerate the development of targeted therapies for this challenging condition, reflecting the company's commitment to enhancing patient outcomes. This initiative helped boost sales and revenue.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biodesix, Inc.
  • Genentech, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • PerkinElmer, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Novartis International AG
  • Johnson & Johnson
  • Mylan N.V.
  • Sanofi S.A.
  • Amgen Inc.

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY TYPE OF BIOMARKERS- MARKET ANALYSIS, 2019 - 2032

  • Diagnostic Biomarkers
  • Prognostic Biomarkers
  • Predictive Biomarkers

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Diagnosis
  • Treatment Monitoring
  • Drug Development

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pulmonary Fibrosis Biomarkers Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pulmonary Fibrosis Biomarkers Market Snippet by Type of Biomarkers
    • 2.1.2. Pulmonary Fibrosis Biomarkers Market Snippet by Application
    • 2.1.3. Pulmonary Fibrosis Biomarkers Market Snippet by End-user
    • 2.1.4. Pulmonary Fibrosis Biomarkers Market Snippet by Country
    • 2.1.5. Pulmonary Fibrosis Biomarkers Market Snippet by Region
  • 2.2. Competitive Insights

3. Pulmonary Fibrosis Biomarkers Key Market Trends

  • 3.1. Pulmonary Fibrosis Biomarkers Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pulmonary Fibrosis Biomarkers Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pulmonary Fibrosis Biomarkers Market Opportunities
  • 3.4. Pulmonary Fibrosis Biomarkers Market Future Trends

4. Pulmonary Fibrosis Biomarkers Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pulmonary Fibrosis Biomarkers Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pulmonary Fibrosis Biomarkers Market Landscape

  • 6.1. Pulmonary Fibrosis Biomarkers Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pulmonary Fibrosis Biomarkers Market - By Type of Biomarkers

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Biomarkers, 2024 & 2032 (%)
    • 7.1.2. Diagnostic Biomarkers
    • 7.1.3. Prognostic Biomarkers
    • 7.1.4. Predictive Biomarkers

8. Pulmonary Fibrosis Biomarkers Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Diagnosis
    • 8.1.3. Treatment Monitoring
    • 8.1.4. Drug Development

9. Pulmonary Fibrosis Biomarkers Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 9.1.2. Hospitals & Clinics
    • 9.1.3. Diagnostic Laboratories
    • 9.1.4. Research & Academic Institutions

10. Pulmonary Fibrosis Biomarkers Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Pulmonary Fibrosis Biomarkers Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Biodesix, Inc.
    • 11.2.2. Genentech, Inc.
    • 11.2.3. F. Hoffmann-La Roche Ltd.
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. AbbVie Inc.
    • 11.2.6. Thermo Fisher Scientific Inc.
    • 11.2.7. Abbott Laboratories
    • 11.2.8. PerkinElmer, Inc.
    • 11.2.9. Eli Lilly and Company
    • 11.2.10. Gilead Sciences, Inc.
    • 11.2.11. Novartis International AG
    • 11.2.12. Johnson & Johnson
    • 11.2.13. Mylan N.V.
    • 11.2.14. Sanofi S.A.
    • 11.2.15. Amgen Inc.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us